We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
-8.18%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.06B
AUM Growth
-$181M
(-15%)
Cap. Flow
-$8.21M
Cap. Flow
% of AUM
-0.78%
Top 10 Holdings %
Top 10 Hldgs %
88.26%
Holding
30
New
–
Increased
4
Reduced
4
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVRO
NEVRO CORP.
NVRO
|
+$4.28M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
+$4.22M |
| 3 |
Gossamer Bio
GOSS
|
+$3.53M |
| 4 |
NovoCure
NVCR
|
+$2.37M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$11.9M |
| 2 |
Align Technology
ALGN
|
+$6.53M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
+$2.65M |
| 4 |
GRTS
Gritstone bio, Inc. Common Stock
GRTS
|
+$1.3M |
| 5 |
Vanda Pharmaceuticals
VNDA
|
+$251K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.08% |
| 2 | Financials | 1.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Aldeyra Therapeutics
ALDX
$91.7M
| $1.07M | 0.1% |
160,800
| – | – |
|
|
KZR
27
DELISTED
Kezar Life Sciences
KZR
| $781K | 0.07% |
65,620
| – | – |
|
28
Tactile Systems Technology
TCMD
$555M
| $381K | 0.04% |
27,100
| – | – |
|
29
UroGen Pharma
URGN
$2.39B
| $343K | 0.03% |
24,500
| – | – |
|
|
GRTS
30
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| – | – |
-666,127
| Closed | -$1.3M |
|
Similar funds
AG
BL
PIM
ACA
PCM
HCM
ACM
DC
Palo Alto Investors's Q3 2023 Portfolio in Review
As of Q3 2023, Palo Alto Investors held 30 positions worth $1.06B, down 15% from $1.24B the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Trading was light in Q3 2023: portfolio turnover was 3.3%. Palo Alto Investors opened no new positions and exited 1, leaving the 30-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials.
- Palo Alto Investors added most to NEVRO CORP. in Q3 2023, an estimated $4.28M increase.
- Palo Alto Investors's biggest Q3 2023 reduction was United Therapeutics, cutting an estimated $11.9M.
- Palo Alto Investors fully exited Gritstone bio, Inc. Common Stock in Q3 2023, selling an estimated $1.3M.
- Palo Alto Investors's ten largest holdings make up 88% of its $1.06B portfolio in Q3 2023.
- Palo Alto Investors opened 0 new positions and closed 1 in Q3 2023.
- Palo Alto Investors's portfolio value fell 15% quarter-over-quarter to $1.06B.
Based on Palo Alto Investors's 13F filing for Q3 2023, filed 14 Nov 2023.